[New evidence of uselessness of intravenous glucose-insulin-potassium infusion in patients with ST-segment elevation myocardial infarction: results of meta-analysis of CREATE-ECLA and OASIS-6 trials].
D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002314:Cardioplegic Solutions / Q000008:administration & dosage / Q000009:adverse effects; D000075202:Contraindications; D004562:Electrocardiography; D005947:Glucose / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D006943:Hyperglycemia / Q000097:blood / Q000139:chemically induced*; D006947:Hyperkalemia / Q000097:blood / Q000139:chemically induced*; D007262:Infusions, Intravenous; D007328:Insulin / Q000008:administration & dosage / Q000009:adverse effects; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D011188:Potassium / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012307:Risk Factors; D015996:Survival Rate / Q000639:trends
D001786:Blood Glucose; D002314:Cardioplegic Solutions; D007328:Insulin; C030396:glucose-insulin-potassium cardioplegic solution; D005947:Glucose; D011188:Potassium